Nanoparticle-mediated siRNA delivery systems for cancer therapy

Research output: Contribution to journalReview ArticleScientificpeer-review

Abstract

The small interfering RNA (siRNA)‐based therapeutics have raised great attention since the first RNA interference (RNAi)‐derived drug, patisiran, was approved by the US Food and Drug Administration, which represented a landmark in the field of gene therapy. Given the properties of interfering disease‐associated gene expression, RNAi machinery is regarded as an essential factor for preparing precise medicine. However, over the past few years, siRNA drugs are undergoing a period of clinical translation, in which the major hurdle is the limited efficient delivery strategies. Therefore, this mini‐review mainly focuses on describing the state‐of‐the‐art of the nanoscale platforms for delivering siRNA payloads, also addressing their applications in cancer therapy. Finally, the status of siRNA drugs under clinical trials is discussed, providing a comprehensive understanding on the field of oligonucleotide‐mediated therapeutics.
Original languageEnglish
Article number20200111
JournalView
Volume2
Issue number3
Number of pages12
ISSN2688-3988
DOIs
Publication statusPublished - Jun 2021
MoE publication typeA2 Review article in a scientific journal

Fields of Science

  • BLOCKADE
  • EFFICACY
  • ENDOSOMAL ESCAPE
  • FIBROBLASTS
  • FIBROSIS
  • LIPID NANOPARTICLES
  • MACROPHAGES
  • RNA
  • STRATEGY
  • TUMOR MICROENVIRONMENT
  • cancer therapy
  • nanomedicine
  • nanoparticles
  • small interfering RNA
  • 318 Medical biotechnology
  • 317 Pharmacy
  • 3122 Cancers

Cite this